Items Tagged ‘nivolumab’

November 28th, 2016

Opdivo Approved for Advanced Head and Neck Cancer

By

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the head and neck cancer (SCCHN) that has spread to distant sites in the body and has progressed or […]

View full entry

Tags: fda, General Head and Neck Cancer, Head and Neck Cancer, News, nivolumab, opdivo, schhn


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


August 16th, 2016

Opdivo® Highly Effective for Some Patients with Lymphomas

By

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal of Clinical Oncology. Lymphomas are a type of cancer that arise in immune cells. There are two main types of immune […]

View full entry

Tags: diffuse large B-cell lymphoma, Follicular Lymphoma, Lymphoma, News, nivolumab, Non-Hodgkin's Lymphoma, opdivo, peripheral T-cell lymphoma, T-Cell Non-Hodgkin's Lymphoma


June 6th, 2016

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows

By

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options. A new Moffitt Cancer study being presented at the ASCO Annual Meeting in Chicago and published in The […]

View full entry

Tags: 2016, asco, Checkmate 032, immunotherapy, ipilmumab, Lung Cancer, Lung Cancer - Small Cell, molecule PD-1, News, nivolumab, sclc, small cell lung cancer


May 25th, 2016

More Evidence that PD-1 Inhibitors Improve Survival in Head and Neck Cancer

By

Results from a recent large trial indicate that treatment with the immunotherapy agent Opdivo® (nivolumab) nearly doubles the survival rate at one year in patients with advanced head and neck squamous cell carcinoma. These results prompted the United States Food and Drug Administration to grant Opdivo “breakthrough therapy designation” for the treatment of patients with […]

View full entry

Tags: Breakthrough Therapy Designation, CheckMate 141 clinical trial, fda, General Head and Neck Cancer, Head and Neck Cancer, News, nivolumab, opdivo, squamous cell


November 25th, 2015

FDA Approves Opdivo for Renal Cell Carcinoma

By

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung cancer. About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: General Renal Cancer, kidney cancer, News, nivolumab, opdivo, rcc, Renal Cancer, renal cell cancer


November 10th, 2015

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer

By

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published in the New England Journal of Medicine while simultaneously being presented at the 2015 European Cancer Congress. Lung cancer remains […]

View full entry

Tags: advanced, docetaxel, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-squamous, nsclc, opdivo, PD-1 inhibitor, Recurrent Lung Cancer - Non-Small Cell, squamous


October 19th, 2015

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer

By

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into two main groups based upon the type of cells comprising the cancer: non-squamous and squamous cell. […]

View full entry

Tags: FDA approval, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, non-squamous, nsclc, opdivo, Stages I-IIIA Lung Cancer - Non-Small Cell


September 10th, 2015

Updated Trial Results Demonstrating Benefit of Opdivo® Were Released Today at the 16th World Conference on Lung Cancer

By

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference on Lung Cancer (Abstract #736), and the studies showed sustained survival benefit. Both trials showed an estimated 18-month overall survival (OS) rate of 27% (CheckMate […]

View full entry

Tags: CheckMate, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV


July 29th, 2015

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival

By

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase III clinical trial. Because the improved survival with Opdivo was apparent sooner than expected, the trial has been stopped early. Each year in the United States, […]

View full entry

Tags: General Renal Cancer, kidney cancer, News, nivolumab, opdivo, rcc, Renal Cancer, renal cell carcinoma


June 29th, 2015

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma

By

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England Journal of Medicine. Standard treatment for advanced melanoma typically […]

View full entry

Tags: advanced melanoma, ipilimumab, Melanoma, News, nivolumab, opdivo, Stage III Melanoma, Stage IV Melanoma, Yervoy


April 24th, 2015

Nivolumab

By

Class: Biological Therapy Generic Name: Nivolumab Trade Name: Opdivo® For which conditions is this drug approved? Opdivo is approved to treat melanoma that: a) can’t be removed by surgery; or b) metastatic melanoma that’s progressed after treatment with Yervoy® (ipilimumab) or, if BRAF V600 mutation positive, progressed after treatment with a BRAF inhibitor. Opdivo is […]

View full entry

Tags: Biological Therapy, Drug Dictionary, N, nivolumab


December 23rd, 2014

FDA Approves Nivolumab for Advanced Melanoma

By

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab (Yervoy) and, for melanoma patients whose tumors express the BRAF V600 mutation, for use after treatment with ipilimumab […]

View full entry

Tags: fda, Melanoma, News, nivolumab, opdivo, PD-1, Recurrent Melanoma, Stage IV Melanoma


December 18th, 2014

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of Medicine, PD-1 blockade has demonstrated effectiveness in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is a […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, HL, Hodgkin's Lymphoma, Lymphoma, News, nivolumab, PD-1, Progressive Relapsed Hodgkin's Lymphoma


November 20th, 2014

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma

By

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently published online in the New England Journal of Medicine.[1] Of the more than one million new diagnoses of skin cancer each year, […]

View full entry

Tags: immunotherapy, Melanoma, melaoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma